KOSDAQBiotech & Pharma376900

Rokit Healthcare

₩15,470▼ 2.09%2026-11-18 close
Market Cap
₩270.6B
Turnover
₩1.8B
Volume
120K
Shares out.
17.5M
PER
—
PBR
—
EPS
-₩1,315
Dividend Yield
0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩0 per share · Prices as of the 2026-11-18 close

01

Report overview

Revenue doubled, but losses have run three quarters

Rokit Healthcare doubled revenue in 2025 and turned operating profit positive, but operating losses have persisted for three straight quarters through the third quarter of 2026, with revenue growth and investment costs pulling in opposite directions.

  1. 1

    Revenue reached KRW 26.2 billion in 2025, up 100.2% from the prior year, and operating profit of KRW 453 million marked a turn from the prior-year operating loss.

  2. 2

    Third-quarter 2026 revenue fell to KRW 6.13 billion, down 25.4% from the prior quarter, while the operating loss narrowed to KRW 9.48 billion from KRW 13.5 billion in the second quarter.

  3. 3

    The net loss attributable to controlling shareholders widened to KRW 9.34 billion in the second quarter and KRW 9.87 billion in the third quarter of 2026, totaling KRW 21.4 billion over the last four quarters.

  4. 4

    On November 10, 2026, the company announced a roadmap to invest KRW 65.4 billion across six fields through 2028, treating 2026 to 2027 as the core period.

  5. 5

    At the end of 2025, total equity stood at KRW 11.6 billion against total liabilities of KRW 43.5 billion, and operating cash flow was -KRW 17.2 billion, the largest outflow in the period shown.

02

Business structure

Rokit Healthcare is a regenerative medicine company built around an AI-based long-term regeneration platform, combining three-dimensional (3D) bioprinting with patient autologous tissue technology.

According to its business report, besides equipment sales, recurring revenue from consumable regeneration kits and maintenance programs is becoming a core part of the revenue structure. Its fields cover skin, cartilage, kidney and hair regeneration, plus AI disease prediction and anti-aging.

Skin regeneration is the lead field, extending overseas from its experience treating chronic hard-to-heal wounds such as diabetic foot ulcers. Cartilage regeneration is in clinical trials involving about 80 patients.

Kidney regeneration is developing an omentum-based patch using the patient's own tissue, fused with AI and 3D bioprinting. The AI prediction field includes AI-based kidney function analysis, and the company plans an integrated service linking disease prediction, prevention and regenerative treatment.

By region, 43.9% of 2025 revenue came from overseas, with sales contracts in 46 countries. In China, it formed a strategic partnership with WEGO Group, a leading medical device company, to commercialize its AI long-term regeneration platform.

Competition differs by field: skin regeneration competes in the wound-care market, while cartilage and kidney regeneration hinge on securing clinical evidence, so technical validation and overseas approvals are the gateways to expansion.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩7B₩77,538,6481.1%
2025Q4₩9.6B₩600M6.3%
2026Q1₩8.1B-₩2.4B−29.2%
2026Q2₩8.2B-₩13.5B−163.7%
2026Q3₩6.1B-₩9.5B−154.6%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩9.2B-₩13.9B₩1.9B−151.7%—−114.5%
2023₩12.4B-₩7.4B₩16.6B−59.4%—−110.8%
2024₩13.1B-₩5.6B-₩7.6B−42.5%—−114.7%
2025₩26.2B₩500M-₩2.8B1.7%−24.6%376.3%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-13

04

Earnings analysis

On a disclosed basis, revenue rose from KRW 9.15 billion in 2022 to KRW 12.4 billion in 2023 (up 35.7% year on year) and KRW 13.1 billion in 2024 (up 5.6%), then reached KRW 26.2 billion in 2025 (up 100.2%).

Revenue has risen for three consecutive years from 2023 through 2025, and 2025 is the largest year in the 2022 to 2025 span.

Operating results moved from an operating loss of KRW 13.9 billion in 2022, KRW 7.38 billion in 2023 and KRW 5.57 billion in 2024, with the losses narrowing each year, to an operating profit of KRW 453 million in 2025. The operating margin shifted from -151.7% in 2022 to 1.7% in 2025.

Net income attributable to controlling shareholders rose to KRW 16.6 billion in 2023 (up 785.6%), then turned into a loss of KRW 7.65 billion in 2024 and narrowed to a loss of KRW 2.85 billion in 2025.

For 2024, the audited net loss came in wider than the pre-audit figure in the securities filing; the company attributed the gap to accounting losses from derivative valuation and provision rate adjustments.

The company also said the 2025 net loss reflected accounting valuation losses on convertible bonds and other instruments. Operating cash flow was -KRW 6.59 billion in 2022, -KRW 3.92 billion in 2023 and -KRW 5 billion in 2024, then widened to -KRW 17.2 billion in 2025.

Quarterly revenue climbed from KRW 6.95 billion in the third quarter of 2025 to KRW 9.58 billion in the fourth quarter (up 37.8% from the prior quarter), then moved to KRW 8.06 billion in the first quarter of 2026 (down 15.9%), KRW 8.22 billion in the second quarter, and KRW 6.13 billion in the third quarter (down 25.4%).

Operating profit of KRW 600 million in the fourth quarter of 2025 was followed by operating losses of KRW 2.35 billion, KRW 13.5 billion and KRW 9.48 billion in the first three quarters of 2026, three straight quarters of losses.

For the first-quarter 2026 loss, the company cited costs concentrated on future revenue sources, including global clinical expansion of its AI cartilage regeneration platform, kidney prediction diagnostics and regulatory response.

05

Industry analysis

Regenerative medicine restores damaged function using cells and tissue, and commercialization depends on developing treatment technology, clinical evidence and an approval pathway together.

Rokit Healthcare seeks differentiation by combining 3D bioprinting with patient autologous tissue, expanding its technology across skin, cartilage and kidney fields. According to press reports, the Chinese skin regeneration market is estimated at KRW 1.4 trillion, and the company partnered with WEGO Group to target it.

In Europe, the company began supplying its AI skin regeneration platform to a public hospital in Milan, Italy, in February 2026, which it said secured a foothold in European public healthcare.

Domestically, both kidney and cartilage regeneration are pursuing the advanced regenerative medicine treatment plan route to build clinical evidence.

In cycle terms, revenue is growing on the back of overseas distribution, while earnings sit in an early commercialization phase where clinical and regulatory investment is heavy.

Unlike large biopharma names such as Samsung Biologics or Celltrion, which operate on production and sales scale, Rokit Healthcare is a small regenerative medicine company spending on platform development and clinical data, so the comparison axes differ.

Competitively, skin regeneration meets wound-care technology companies, while cartilage and kidney regeneration meet clinical-stage developers.

06

Outlook

The company set 2026 to 2027 as the core period for building its global AI regenerative medicine platform and transforming its business.

In its roadmap announced on November 10, 2026, it said it will invest a total of KRW 65.4 billion through 2028 across six fields: skin, cartilage, kidney and hair regeneration, AI disease prediction, and anti-aging.

Cartilage regeneration trials currently involve about 80 patients, and the company aims to complete enrollment of 104 patients within November 2026. After enrollment, it plans to pursue an advanced regenerative medicine treatment plan application in Korea, overseas approvals and broader commercialization.

Kidney regeneration is pursuing a domestic treatment plan application and plans to verify in clinical studies whether it can preserve kidney function and delay the start of dialysis. Hair regeneration is in new treatment technology development, with overseas market entry under review over the longer term.

The company said its entry into the United States, Saudi Arabia and Latin America is proceeding as planned. Press reports said the Nasdaq listing process for its US subsidiary Rokit America has moved forward, and the listing timing and terms will be clarified in future disclosures.

In its first-quarter 2026 results, the company stressed that securing global standing for its AI long-term regeneration platform and accumulating clinical data matter more than maximizing short-term profit.

If investment outpaces revenue growth for an extended period, the operating loss structure could persist, while on-schedule enrollment and approvals could shift the revenue mix from 2027. The next checkpoint is the annual operating result and cash flow in the 2026 business report.

07

Valuation

PER
—
PBR
—
ROE
-122.3%
EPS
-₩1,315
BPS
—
Dividend per share
₩0

Rokit Healthcare has been in a net loss position over the last four quarters, so a price-to-earnings ratio based on earnings cannot be calculated. Valuation is therefore better read through relationships with other measures, such as net asset value, revenue scale and the profit trend.

Total equity at the end of 2025 was KRW 11.6 billion, and equity attributable to controlling shareholders was the same KRW 11.6 billion. The negative debt ratios shown for 2022 through 2024 reflected a capital structure with negative total equity, which turned positive by the end of 2025.

Market capitalization sits well above book equity, a premium relative to net asset value. Because there are no earnings, direct comparison with profitable peers in the same sector is difficult, so revenue growth, the operating loss trend and funding status are useful to read together.

Dividend-based evaluation is not feasible because no earnings-based dividend pattern is confirmed. Comparisons with historical valuation bands should specify the date, since they shift with the share price.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-13

08

Bull factors

Rapid revenue expansion

Revenue rose from KRW 9.15 billion in 2022 to KRW 26.2 billion in 2025, and press reports citing the company disclosure said first-quarter 2026 revenue grew 118% year on year. The business report indicates 43.9% of 2025 revenue came from overseas, with sales contracts in 46 countries. Press reports said 2025 results exceeded the KRW 23.7 billion estimate in the securities filing.

Operating profit turnaround

Operating profit was KRW 453 million in 2025 after an operating loss in 2024, and the operating margin improved from -151.7% in 2022 to 1.7% in 2025. The fourth quarter of 2025 posted an operating profit of KRW 600 million, the one quarter of profit in the recent run. The shift from losses to profit marks a change in the direction of the business.

Pipeline and clinical progress

On November 10, 2026, the company announced a roadmap to invest KRW 65.4 billion across six fields through 2028. Cartilage regeneration targets completing enrollment of 104 patients within November 2026, and kidney regeneration is pursuing a domestic advanced regenerative medicine treatment plan application. Clinical progress provides the evidence base for technology validation and overseas approvals.

09

Bear factors

Persistent quarterly operating losses

The operating loss was KRW 13.5 billion in the second quarter of 2026 and KRW 9.48 billion in the third quarter, three straight quarters of losses. Third-quarter revenue fell to KRW 6.13 billion, down 25.4% from the prior quarter. The net loss attributable to controlling shareholders totals KRW 21.4 billion over the last four quarters.

Financial capacity and cash outflow

Total liabilities at the end of 2025 were KRW 43.5 billion, well above total equity of KRW 11.6 billion, with a debt ratio of 376.3%. Operating cash flow was -KRW 17.2 billion in 2025, the largest outflow since 2022. Additional fundraising has been raised as a possibility as clinical costs rise.

Accounting and disclosure credibility

The audited 2024 net loss came in well above the pre-audit figure in the securities filing, and in March 2025 the Financial Supervisory Service reportedly said it would review the gap alongside the outlook.

The company attributed the loss to accounting items such as derivative valuation losses and provision rate changes. The episode remains a reference point for judging the reliability of its earnings outlook.

10

Risk factors

Clinical and regulatory timing

If cartilage enrollment of 104 patients and the domestic treatment plan application slip, commercialization timing could be delayed. Overseas approvals carry country-specific regulatory costs. The first-quarter 2026 operating loss already included global regulatory and approval expenses.

Funding and dilution

With liabilities of KRW 43.5 billion well above equity, valuation losses on convertible bonds have swung the bottom line. The company said conversion of the bonds would strengthen capital. However, conversion increases the share count, which can affect the value of existing shareholders' stakes.

Execution load of overseas expansion

Entering the United States, Saudi Arabia and Latin America at once increases the burden of local regulation and partner management. The China plan depends on the partnership with WEGO Group. With 43.9% of revenue from overseas, exchange rates and local policy changes could also affect results.

11

What to watch next

  1. Late November 2026

    This is the target for completing enrollment of 104 patients in the cartilage trial. Whether it is met will signal the pace of expansion and the timing of the domestic advanced treatment plan application.

  2. During the 2026 to 2027 core period

    Checkpoints include progress on the domestic treatment plan application for kidney regeneration and early results on kidney function preservation. Clinical results would indicate the pace of overseas approval efforts.

  3. By March 31, 2027

    This is the deadline for the 2026 annual business report. Confirmed 2026 revenue, operating results, cash flow and debt structure will be disclosed, allowing comparison with the sum of the 2026 quarterly figures.

  4. Date to be announced

    Progress of the Nasdaq listing process for US subsidiary Rokit America. Once timing and terms are disclosed, changes to the funding structure and shareholding can be assessed.

12

Overall view

Rokit Healthcare showed change in its scale and profit structure, with 2025 revenue of KRW 26.2 billion (up 100.2% year on year) and a turn to operating profit.

Yet operating losses have continued for three straight quarters in 2026, and the net loss attributable to controlling shareholders totals KRW 21.4 billion over the last four quarters.

Third-quarter 2026 revenue of KRW 6.13 billion fell from the prior quarter, and the company attributes the losses to clinical and technology investment.

The bull case rests on overseas revenue share, pipeline expansion and the KRW 65.4 billion investment plan, while the bear case rests on cash outflow, the debt structure, funding needs and questions over the reliability of its earnings outlook. The two readings diverge depending on which time frame is emphasized.

The next checkpoints are the completion target for cartilage trial enrollment in late November 2026 and the 2026 business report due by March 31, 2027, which will show the direction of full-year 2026 operating results and cash flow.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 18 more articles and sources
  1. hitnews.co.kr
  2. butler.works
  3. alphasquare.co.kr
  4. medicopharma.co.kr
  5. topdaily.kr
  6. v.daum.net
  7. m.thinkpool.com
  8. m.news.nate.com
  9. economist.co.kr
  10. m.news.nate.com
  11. newstopkorea.com
  12. sale.mimint.co.kr
  13. medipana.com
  14. biotimes.co.kr
  15. view.asiae.co.kr
  16. job-post.co.kr
  17. news.nate.com
  18. newspost.kr

Report written 2026-11-14 · Data as of 2026-11-13

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis